These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 9321394)

  • 1. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
    Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
    EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M; Slupianek A; Skorski T
    Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
    Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
    Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
    Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
    J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
    Chandrasekher G; Sailaja D
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.
    Skorski T; Wlodarski P; Daheron L; Salomoni P; Nieborowska-Skorska M; Majewski M; Wasik M; Calabretta B
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11858-62. PubMed ID: 9751755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
    Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
    Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
    Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the Ral and phosphatidylinositol 3' kinase signaling pathways by the ras-related protein TC21.
    Rosário M; Paterson HF; Marshall CJ
    Mol Cell Biol; 2001 Jun; 21(11):3750-62. PubMed ID: 11340168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
    Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
    J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
    Jain SK; Susa M; Keeler ML; Carlesso N; Druker B; Varticovski L
    Blood; 1996 Sep; 88(5):1542-50. PubMed ID: 8781408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Wasik M; Trotta R; Kanakaraj P; Salomoni P; Antonyak M; Martinez R; Majewski M; Wong A; Perussia B; Calabretta B
    Blood; 1998 Jan; 91(2):406-18. PubMed ID: 9427693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jak2 is involved in c-Myc induction by Bcr-Abl.
    Xie S; Lin H; Sun T; Arlinghaus RB
    Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage colony-stimulating factor-, granulocyte-macrophage colony-stimulating factor-, or IL-3-dependent survival of macrophages, but not proliferation, requires the expression of p21(Waf1) through the phosphatidylinositol 3-kinase/Akt pathway.
    Comalada M; Xaus J; Sánchez E; Valledor AF; Celada A
    Eur J Immunol; 2004 Aug; 34(8):2257-67. PubMed ID: 15259023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal Cl41 cells.
    Li J; Chen H; Tang MS; Shi X; Amin S; Desai D; Costa M; Huang C
    J Cell Biol; 2004 Apr; 165(1):77-86. PubMed ID: 15067018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.